Unlike most trials that avoid patients who failed other therapies, Corvus intentionally included them, considering it a 'stacking deck against yourself'. This high-risk bet, based on their drug's unique mechanism, paid off by showing efficacy in a tough-to-treat population and demonstrating a lack of cross-resistance.

The approvals of two different oligonucleotide constructs for the same indication (Arrowhead's siRNA vs. IONIS's ASO) mark a significant milestone. This direct competition between RNA modalities signifies a maturing market where companies now focus on determining which molecule is superior for specific targets.

A promising drug can be rendered obsolete if a competitor develops a superior, disease-modifying therapy that eliminates the original market need. This highlights that competitive dynamics are as critical as scientific validity, as when a cystic fibrosis therapy was sidelined by Vertex's core treatment.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

Instead of remaining a pure-play antisense oligonucleotide (ASO) company, Ionis's CEO diversified into siRNA and gene editing. He recognized that the company's core expertise in oligonucleotide therapeutics was broadly applicable, a move that energized the research organization.

Facing industry-wide skepticism in 2010, Alnylam implemented a highly disciplined R&D strategy. They focused exclusively on targets that met strict criteria: liver expression (where delivery worked), human genetic validation (to de-risk biology), and an early biomarker. This strategic focus was key to their survival and success.

CEO Brett Monia pivoted Ionis from a pure R&D partnership model to a fully integrated biotech. He argued that relying on partners stalled promising drugs and suppressed the company's valuation, necessitating the development of in-house commercial capabilities.

When Ionis announced its strategic shift from a partnership model to a wholly-owned pipeline, investors were skeptical due to the company's 30-year history. Despite liking the new vision, they waited for tangible proof, only rewarding the stock after Ionis successfully launched its first independent products.

While large pharma companies invested heavily in RNAi and failed to produce candidates, Alnylam maintained a singular focus. They pushed their technology into human trials to learn and validate it, ultimately succeeding where better-funded competitors with a less focused, product-driven approach failed.